NXERA Pharma announced that vamorolone has been selected as a pilot program to accelerate reimbursement for rare disease treatment in South Korea.

Zhitongcaijing · 2d ago
NXERA Pharma announced that vamorolone has been selected as a pilot program to accelerate reimbursement for rare disease treatment in South Korea.